Fludarabine, Cytarabine, Idarubicin and Etoposide (FLAIE) schedule is safe and active for young patients with newly diagnosed acute myeloid leukemia (AML): Results of a multicentric phase III Italian study

被引：0

作者：

Abbenante, Mariachiara ^{[1
]}

Papayannidis, Cristina ^{[1
]}

Iacobucci, Ilaria ^{[1
]}

Candoni, Anna ^{[2
]}

Paolini, Stefania ^{[1
]}

Malagola, Michele ^{[3
]}

Emanuela, Ottaviani ^{[1
]}

Lonetti, Annalisa ^{[1
]}

Curti, Antonio ^{[1
]}

Parisi, Sarah ^{[1
]}

Testoni, Nicoletta ^{[1
]}

Lama, Barbara ^{[1
]}

Baccarani, Michele ^{[1
]}

Martinelli, Giovanni ^{[1
]}

机构：

[1] Univ Bologna, Dept Hematol Oncol Seragnoli, Bologna, Italy

[2] Div Hematol & BMT, Udine, Italy

[3] Univ Brescia, Hematol & BMT Unit, Brescia, Italy

来源：

CANCER RESEARCH | 2011年 / 71卷

关键词：

D O I：

10.1158/1538-7445.4M2011-2236

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2236

引用

页数：2

共 50 条

[21] Results of a Phase 2, Open-Label Study of Idarubicin (I), Cytarabine (A) and Nivolumab (Nivo) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
Assi, Rita
Kantarjian, Hagop M.
Daver, Naval G.
Garcia-Manero, Guillermo
Benton, Christopher B.
Thompson, Philip A.
Borthakur, Gautam
Kadia, Tapan M.
Alvarado, Yesid
Jabbour, Elias J.
Konopleva, Marina Y.
Takahashi, Koichi
Kornblau, Steven M.
DiNardo, Courtney D.
Estrov, Zeev E.
Flores, Wilmer
Basu, Sreyashi
Allison, James P.
Sharma, Padmanee
Pierce, Sherry A.
Pike, Allison
Cortes, Jorge E.
Ravandi, Farhad
BLOOD, 2018, 132
[22] Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia
Nazha, Aziz
Kantarjian, Hagop
Ravandi, Farhad
Huang, Xuelin
Choi, Sangbum
Garcia-Manero, Guillermo
Jabbour, Elias
Borthakur, Gautam
Kadia, Tapan
Konopleva, Marina
Cortes, Jorge
Ferrajoli, Alessandra
Kornblau, Steve
Daver, Naval
Pemmaraju, Naveen
Andreeff, Michael
Estrov, Zeev
Du, Min
Brandt, Mark
Faderl, Stefan
AMERICAN JOURNAL OF HEMATOLOGY, 2013, 88 (11) : 961 - 966
[23] Results of a Phase 2, Open-Label Study of Idarubicin, Cytarabine, and Nivolumab in Patients With Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (02) : 9 - 11
[24] Preliminary Results of the Flugaza Trial: A Phase III Randomized, Open Label Study Comparing Azacytidine Versus Fludarabine and Cytarabine (FLUGA Scheme) in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia
Montesinos, Pau
Vives, Susana
Martinez-Sanchez, Maria P.
Bergua, Juan
Algarra, Lorenzo
Pilar, Herrera
Tormo, Mar
Lopez-Lorenzo, Jose-Luis
Ramos, Fernando
Falantes, Jose Francisco
Salamero, Olga
Serrano, Josefina
Gil, Cristina
Amador, Maria L.
Lavilla, Esperanza
Sayas, Maria J.
Olave, Maria Teresa
Vidriales, Belen
Martinez-Cuadron, David
Sanz, Miguel Angel
BLOOD, 2016, 128 (22)
[25] Combination of Sorafenib, Idarubicin, and Cytarabine Has a High Response Rate in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Younger Than 65 Years
Ravandi, Farhad
Cortes, Jorge
Faderl, Stefan
Garcia-Manero, Guillermo
O'Brien, Susan
Borthakur, Gautam
Pierce, Sherry
Brandt, Mark
Lang, Marites
Zhang, Weiguo
Luthra, Rajyalakshmi
Jones, Dan
Levis, Mark J.
Konopleva, Marina
Andreeff, Michael
Kantarjian, Hagop M.
BLOOD, 2008, 112 (11) : 285 - 285
[26] Final Report of a Phase II Trial of Vorinostat with Idarubicin and Cytarabine for Patients with Newly Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Garcia-Manero, Guillermo
Tambaro, Francesco Paolo
Bekele, Nebiyou
Yang, Rui
Ravandi, Farhad
Jabbour, Elias
Borthakur, Gautam
Kadia, Tapan
Konopleva, Marina
Faderl, Stefan
Cortes, Jorge E.
Brandt, Mark
Hu, Yumin
McCue, Deborah
Newsome, Willie Mae
Pierce, Sherry
DeLima, Marcos
Kantarjian, Hagop M.
BLOOD, 2011, 118 (21) : 346 - 347
[27] Phase II Study of the Combination of Clofarabine Plus Idarubicin and Cytarabine (CIA) In Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
Naqvi, Kiran
Ravandi, Farhad
Kantarjian, Hagop
Borthakur, Gautam
Ferrajoli, Alessandra
Thomas, Deborah A.
Koller, Charles Asa
Konopleva, Marina
Byrd, Anna
Kwari, Monica
Faderl, Stefan
BLOOD, 2010, 116 (21) : 464 - 465
[28] A Phase 1 Study of Sequential Idarubicin plus Cytarabine, Followed by Lenalidomide, in Patients with Previously Untreated Acute Myeloid Leukemia (AML)
Lancet, Jeffrey E.
Komrokji, Rami S.
Yu, Daohai
Advani, Anjali S.
Searles, Tammy
Sekeres, Mikkael A.
List, Alan F.
BLOOD, 2011, 118 (21) : 1115 - 1116
[29] Phase II Trial of Vorinostat With Idarubicin and Cytarabine for Patients With Newly Diagnosed Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Garcia-Manero, Guillermo
Tambaro, Francesco Paolo
Bekele, Nebiyou B.
Yang, Hui
Ravandi, Farhad
Jabbour, Elias
Borthakur, Gautam
Kadia, Tapan M.
Konopleva, Marina Y.
Faderl, Stefan
Cortes, Jorge E.
Brandt, Mark
Hu, Yumin
Mccue, Deborah
Newsome, Willie Mae
Pierce, Sherry R.
de Lima, Marcos
Kantarjian, Hagop M.
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (18) : 2204 - 2210
[30] Fludarabine, Cytarabine, and Attenuated-Dose Idarubicin (m-FLAI) Induction for Elderly Patients with Acute Myeloid Leukemia: Results of a Multicenter Phase II Study
Lim, Yoojoo
Koh, Youngil
Yoon, Sung-Soo
Park, Seonyang
Kim, Byoung Kook
Kim, Dae-Young
Lee, Jung-Hee
Lee, Kyoo-Hyung
Cheong, June-Won
Kim, Hyuk
Joo, Young Don
Won, Jong-Ho
Park, Sung-Kyu
Kim, Se Hyung
Hong, Dae Sik
Park, Eunkyung
Kim, Min Kyoung
Sohn, Sang Kyun
Kim, Sung Hyun
Lee, Hong-Kee
Kim, Chul Soo
Estey, Elihu H.
Lee, Je-Hwan
Min, Yoo-Hong
Kim, Inho
BLOOD, 2011, 118 (21) : 1549 - 1549

← 1 2 3 4 5 →